Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals Inc (BCRX) is a biotechnology leader developing innovative therapies for rare diseases and infectious conditions through targeted enzyme inhibition. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access authoritative reporting on BCRX's pipeline progress, including updates on hereditary angioedema treatments and antiviral therapies. Our curated collection features earnings announcements, research breakthroughs, and partnership disclosures – all essential for tracking this biopharma innovator.
Key updates include FDA decisions, clinical trial results, and scientific publications. Bookmark this page for streamlined access to verified BioCryst news, eliminating the need to monitor multiple sources. Check regularly for developments impacting the company's position in enzyme inhibitor therapeutics and rare disease treatment markets.
BioCryst Pharmaceuticals (Nasdaq:BCRX) presented findings from patient surveys on hereditary angioedema (HAE) treatments. Results revealed that patients using injectable therapies (Takhzyro®, Haegarda®, Cinryze®) experienced a mean of 0.9 to 1.8 breakthrough attacks in three months. Notably, 85% of respondents reported using preventative medications, with 21% expecting zero attacks within a year. The data was shared at the European Academy of Allergy and Clinical Immunology Digital Congress, indicating a strong demand for new oral treatment options.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced positive data from the APeX-2 and APeX-S clinical trials for berotralstat, an oral treatment for hereditary angioedema (HAE). Over 48 weeks, patients experienced significant reductions in attack frequency and improvements in quality of life scores. In APeX-2, attack rates dropped from 2.9 to 1.0 per month, while in APeX-S, 73% of patients reported zero attacks in the last six months. Berotralstat was well tolerated, with similar adverse events to placebo. The findings were presented at the EAACI Digital Congress.
BioCryst Pharmaceuticals (BCRX) granted inducement options for 147,500 shares to five newly-hired employees on May 29, 2020. The options have an exercise price set at $4.50, matching the stock's closing price before the grant. They vest in four equal annual installments starting one year from the grant date and have a 10-year term in line with BioCryst’s Inducement Equity Incentive Plan. This initiative aligns with NASDAQ Listing Rule 5635(c)(4) and aims to attract talent to advance BioCryst's innovative drug development portfolio.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has successfully completed a public offering of 22,044,447 shares of common stock, generating approximately $115 million in gross proceeds. This includes the full exercise of underwriters’ options for 3,333,334 shares and pre-funded warrants for up to 3,511,111 shares. The funds will be utilized for various purposes, including the development of berotralstat and BCX9930, regulatory activities, and general corporate needs.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in the Jefferies Virtual Healthcare Conference on June 4, 2020, at 10:30 a.m. ET. The event aims to showcase the company's innovations in treating rare diseases through novel, oral, small-molecule medicines. Noteworthy development programs include berotralstat for hereditary angioedema and BCX9930, an oral Factor D inhibitor. A live audio webcast of the presentation will be available on BioCryst's website for investors.
BioCryst Pharmaceuticals (BCRX) has priced an underwritten public offering of 18,711,113 shares at $4.50 per share, alongside pre-funded warrants for an additional 3,511,111 shares at $4.49 each. The total gross proceeds are expected to reach $100 million before expenses. The offering will close around June 1, 2020, pending customary conditions. Proceeds will support various corporate initiatives, including development of berotralstat and BCX9930, among others. J.P. Morgan and Piper Sandler are managing the offering.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced it will present new data on berotralstat (BCX7353), an oral therapy for hereditary angioedema (HAE), at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) digital congress from June 6-8. Key data include findings from the APeX-S and APeX-2 studies, showcasing berotralstat's long-term safety and significant reduction in HAE attacks. As regulatory approvals approach in the U.S., Japan, and EU, Dr. William Sheridan emphasized berotralstat's potential impact on HAE patients.
BioCryst Pharmaceuticals (Nasdaq: BCRX) will present at the Bank of America 2020 Healthcare Conference on May 14, 2020 at 9:00 a.m. ET and at the 2020 RBC Capital Markets Global Healthcare Conference on May 20, 2020 at 3:40 p.m. ET. Both events will be conducted virtually.
Investors can access live webcasts and replays of these presentations on BioCryst's website. The company focuses on developing novel, oral treatments for rare diseases, including berotralstat for hereditary angioedema and BCX9930, an oral Factor D inhibitor.
BioCryst Pharmaceuticals (BCRX) announced the grant of inducement stock options totaling 525,000 shares to two newly-hired employees, including 500,000 shares to CFO Anthony Doyle. The options, granted on April 30, 2020, have an exercise price of $3.91, equal to the stock's closing price on the previous day. Mr. Doyle's options include a vesting schedule tied to his employment status, while the other employee's options vest over four years. These grants comply with NASDAQ Listing Rule 5635(c)(4), aimed at attracting talent to support BioCryst's ongoing development in rare diseases.
FAQ
What is the current stock price of Biocryst Pharmaceuticals (BCRX)?
What is the market cap of Biocryst Pharmaceuticals (BCRX)?
